Key result
Seminal plasma CNP and proCNP concentrations were markedly increased with increased prostate cancer tumor burden (p < 0.0001).
Why the study?
Are C-type natriuretic peptide (CNP) and its precursor (proCNP) associated with tumor burden in human prostate cancer?
Observational
Are C-type natriuretic peptide (CNP) and its precursor (proCNP) associated with tumor burden in human prostate cancer?
CNP and proCNP in seminal plasma may serve as novel biomarkers for assessing tumor burden in prostate cancer.
Supports seminal CNP/proCNP as prostate cancer biomarkers; leaves open clinical utility pending prospective studies.
AIM: Seminal plasma offer a more organ-specific matrix for markers in prostatic disease. We hypothesized that C-type natriuretic peptide (CNP) expression may constitute such a new target. METHODS: Patients with benign prostatic hyperplasia, clinically localized and metastatic prostate cancer were examined for CNP and CNP precursor (proCNP) concentrations in blood and seminal plasma. Furthermore, CNP and the CNP receptor (NPR-B) mRNA contents in tissue from prostate and seminal vesicles were analyzed by qPCR. RESULTS: CNP and NPR-B concentrations decreased with increasing tumor burden (p = 0.0027 and p = 0.0096, respectively). In contrast, seminal plasma CNP and proCNP concentrations were markedly increased with increased tumor burden (p < 0.0001 and p < 0.0001, respectively). CONCLUSION: CNP/proCNP could be new markers in human prostate cancer.
No takes yet. Share an insight, caveat, or question.
Lippert et al. (2015) conducted an observational in Prostate cancer and benign prostatic hyperplasia. Prostate cancer tumor burden vs. Lower tumor burden or benign prostatic hyperplasia was evaluated on CNP and proCNP concentrations in seminal plasma (p=<0.0001). Seminal plasma CNP and proCNP concentrations were markedly increased with increased prostate cancer tumor burden (p < 0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: